Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease

@article{Deleu2002ClinicalPA,
  title={Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease},
  author={Dirk Deleu and Margaret G. Northway and Yolande Hanssens},
  journal={Clinical Pharmacokinetics},
  year={2002},
  volume={41},
  pages={261-309}
}
Current research in Parkinson’s disease (PD) focuses on symptomatic therapy and neuroprotective interventions. Drugs that have been used for symptomatic therapy are levodopa, usually combined with a peripheral decarboxylase inhibitor, synthetic dopamine receptor agonists, centrally-acting antimuscarinic drugs, amantadine, monoamine oxidase-B (MAO-B) inhibitors and catechol-O-methyltransferase (COMT) inhibitors. Drugs for which there is at least some evidence for neuroprotective effect are… 
Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease
  • D. Nyholm
  • Medicine, Biology
    Clinical pharmacokinetics
  • 2006
TLDR
In general, initial dopamine receptor agonist monotherapy is associated with poorer motor performance and lower incidence of motor complications compared with levodopa, and CDS can be approached by optimising the use of dopaminergic drugs based on pharmacokinetic data.
Drug-drug interactions with levodopa modulating treatment responses in Parkinson's disease
  • W. Haefeli
  • Biology, Medicine
    Journal of Neurology
  • 2007
TLDR
A number of frequently used drugs to treat comorbidity have a potential to modify levodopa pharmacokinetics and particularly bioavailability and these drugs may trigger avoidable fluctuations of motor function in patients if not handled appropriately.
Practical aspects of prescribing antiparkinsonian drugs. The place of amantadines in the management of Parkinson’s disease
TLDR
Treatment of Parkinson’s disease includes the administration of dopaminergic and occasionally non-dopaminergic drugs, in mono- or in combination therapy, as well as drugs working on glutamate such as a group of drug with NMDA receptor inhibitor activity (amantadines).
Alternatives to Levodopa in the Initial Treatment of Early Parkinson’s Disease
  • A. Lees
  • Biology, Medicine
    Drugs & aging
  • 2005
TLDR
Synthetic orally acting dopamine agonists have found increasing favour as an option for early PD in relatively young patients and this strategy is based on evidence that this approach may delay the onset of motor fluctuations, at least during the first 5 years of treatment.
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
TLDR
Adjuvant treatment of PD patients experiencing motor fluctuations with entacapone resulted in improvement of motor function and was well tolerated, Therefore, entacAPone presented an acceptable benefit to risk ratio and opicapone appeared to result in a greater therapeutic effect.
[A current view on dopamine receptor agonists in the treatment of Parkinson's disease].
  • N. Titova
  • Medicine, Psychology
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
  • 2015
TLDR
Dopamine receptor agonists (DRA) is a widely used group of antiparkinsonian drugs and has demonstrated an important role in the treatment of Parkinson's disease, with a good control of motor symptoms and the possibility of monotherapy in the early stages of disease.
[A current view on dopamine receptor agonists in the treatment of Parkinson's disease].
TLDR
Dopamine receptor agonists (DRA) is a widely used group of antiparkinsonian drugs and has demonstrated an important role in the treatment of Parkinson's disease, with a good control of motor symptoms and the possibility of monotherapy in the early stages of disease.
Pharmacokinetic-Pharmacodynamic Modeling of Levodopa in Patients With Advanced Parkinson Disease
TLDR
The motor complications during long treatment therapy in patients with advanced PD especially with stage 3 Hoehn and Yahr scale were correlated to the higher plasma concentrations of l-dopa, and pk/pd analysis may be helpful for monitoring the efficiency of therapeutic strategy applied in PD patients.
...
...

References

SHOWING 1-10 OF 295 REFERENCES
Clinical Pharmacokinetics of Anti-Parkinsonian Drugs
TLDR
Amantadine is unique among anti-Parkinsonian agents both in lacking a clearly defined mechanism of action and in being eliminated from the body exclusively by renal excretion of unchanged drug, becoming an important factor in avoiding potential drug toxicity.
Current and emerging strategies in the management of Parkinson's disease : a critical reappraisal
TLDR
The clinical and pharmacokinetic properties of the current and emerging drugs used in the treatment of PD are reviewed and guidelines are provided for the management of early and advanced PD.
Clinical Pharmacology of Dopamine Agonists in Parkinson’s Disease
  • K. Lange
  • Medicine, Biology
    Drugs & aging
  • 1998
TLDR
There is no convincing clinical data to support a neuroprotective effect of dopamine agonists, but it has been suggested that oxidative stress resulting from dopamine metabolism may be reduced by the administration of Parkinson’s disease drugs.
Antiparkinsonian Agents
TLDR
As a selective monoamine oxidase type B (MAO-B) inhibitor, selegiline (deprenyl) is free of the ‘cheese-effect’ when employed in recommended dosages, however, potentially life-threatening drug interactions, with both pethidine (meperidine) and with fluoxetine and other antidepressant medications, have been described.
Pramipexole — a new dopamine agonist for the treatment of Parkinson's disease
Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.
TLDR
There is strong evidence to suggest that selegiline should be considered both in patients newly diagnosed with Parkinson's disease in an attempt to delay symptom progression, and in those experiencing dose-dependent fluctuations in response to levodopa.
Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease. Effect on levodopa bioavailability.
TLDR
It is suggested that chronic anticholinergic intake may contribute to a less predictable pattern of levodopa absorption and related therapeutic response in some subjects.
Concentration-Effect Relationship of Levodopa in Patients with Parkinson’s Disease
TLDR
Findings support some current hypotheses on the origin of, and the pathophysiological process underlying, response fluctuations and there is some evidence that higher plasma concentrations of levodopa are required for similar motor effects when CR preparations are compared with IR preparations.
Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.
TLDR
Pergolide would appear to be at least as useful as other dopamine agonists such as bromocriptine or lisuride for the management of patients with Parkinson's disease when administered in combination with levodopa.
Clinical Pharmacokinetics of Ropinirole
TLDR
Ropinirole shows approximately linear pharmacokinetics when given as single or repeated doses, and is eliminated with a half-life of approximately 6 hours, which is slower for patients older than 65 years compared with those who are younger, and in women taking hormone replacement therapy compared with Those who are not.
...
...